Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors from the central anxious process, conolidine modulates alternate molecular targets. A Science Improvements analyze identified that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabi... https://johnt310ejm4.blog-ezine.com/profile